Galapagos NV
ENXTAMGalapagos NV dropped its Q1 2026 results after market close on May 6, delivering a split verdict that keeps the debate around this Belgian biotech very much alive. The headline read was mixed. Q1 EPS came in at $0.25, well ahead of the consensus estimate of -$1.27 — a beat that ranks Galapagos in the 91st percentile for EPS surprise across the broader universe. Revenue, at…
Snapshot as of 7 May 2026
Galapagos NV dropped its Q1 2026 results after market close on May 6, delivering a split verdict that keeps the debate around this Belgian biotech very much alive. The headline read was mixed. Q1 EPS came in at $0.25,…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for GLPG — free to start on ORTEX.
Sign up for free →Open GLPG on ORTEX